Molecular Subtype
Chronic Myeloid Leukemia, BCR-ABL1 Positive
CI-CAN-00002365CMLExplore in graph →
Hematologic102 active trials3 approved drugs320 evidence items
- NCIt
- C3174
- OncoTree
- CMLBCRABL1
- DOID
- 0081088
- DOID
- 8552
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00002365CMLExplore in graph →
Clinical trials
649 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (104)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07819396 | Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome | not yet recruiting | Phase 2 | 52 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07814560 | Metabolic Syndrome and Risk of Chronic Philadelphia Negative Myeloproliferative Neoplasms(MetSaMyeloprof) | not yet recruiting | — | 313 | Assiut UniversityOTHER |
| 0 |
| Sep 11, 2026 |
| clinicaltrials |
| NCT07710781 | Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies | not yet recruiting | N/A | 300 | Ossium Health, Inc.INDUSTRY | 0 | Sep 10, 2026 | clinicaltrials |
| NCT07804901 | Asciminib Frontline Risk Adapted(ARTIST) | not yet recruiting | Phase 2 | 200 | Prof. Dr. med. Andreas HochhausOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07758218 | Allogeneic iNKT Cell Therapy (agenT-797) After SCT | not yet recruiting | Phase 1 | 22 | University of Wisconsin, MadisonOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07681258 | A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region(ASC4Young) | not yet recruiting | — | 80 | Novartis PharmaceuticalsINDUSTRY | 0 | Aug 10, 2026 | clinicaltrials |
| NCT07740603 | Study of CD38 and CD56 in Chronic Myeloid Leukemia | not yet recruiting | — | 200 | Sohag UniversityOTHER | 0 | Aug 5, 2026 | clinicaltrials |
| NCT07254793 | Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT | not yet recruiting | Phase 1 | 94 | University of ArizonaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07640750 | Efficacy of Asciminib in Real-world in Patients With Chronic Myeloid Leukemia in Second or Subsequent Lines(ASCIRLI) | not yet recruiting | — | 98 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 0 | Jun 11, 2026 | clinicaltrials |
| NCT07518940 | ENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid Leukemia(ENERGIA) | not yet recruiting | N/A | 25 | Carmen FavaOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07413263 | Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia Patients | not yet recruiting | — | 75 | Assiut UniversityOTHER | 0 | Feb 18, 2026 | clinicaltrials |
| NCT07259161 | Modified Conditioning Regimen for CML-BP | not yet recruiting | Phase 2 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Dec 2, 2025 | clinicaltrials |
| NCT07158294 | Identification of BCR::ABL1 Mutations by Digital PCR in CML(DiP-in-CML) | not yet recruiting | N/A | 150 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 0 | Sep 5, 2025 | clinicaltrials |
| NCT07146542 | Expression Pattern and Possible Clinical Significance of CD81 In Myeloid Leukemia | not yet recruiting | — | 66 | Assiut UniversityOTHER | 0 | Aug 28, 2025 | clinicaltrials |
| NCT06865443 | Evaluation of CD47, "Do Not Eat Me" Signal Expression in Chronic Myeloid Leukemia | not yet recruiting | — | 50 | Assiut UniversityOTHER | 0 | Mar 7, 2025 | clinicaltrials |
| NCT06266975 | Chronic Kidney Disease Patient in Chronic Myloied Leukemia | not yet recruiting | — | 40 | Sahar Mohammed GadOTHER | 0 | Feb 20, 2024 | clinicaltrials |
| NCT05440747 | Treatment Free Remission (TFR) in CML Patients （CML-CP）Study | not yet recruiting | — | 203 | Guangdong Provincial People's HospitalOTHER | 0 | Jul 1, 2022 | clinicaltrials |
| NCT05367765 | A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase | not yet recruiting | Phase 4 | 2,400 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 10, 2022 | clinicaltrials |
Data updated 15 days agoSource updated Sep 14, 2026source: clinicaltrials